Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety study of Amelior [ibuprofen] in hospitalized adult orthopedic patients.

Next Previous
X
Search
Trial Profile

Efficacy and safety study of Amelior [ibuprofen] in hospitalized adult orthopedic patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibuprofen (Primary)
  • Indications Postoperative pain
  • Focus Therapeutic Use
  • Sponsors Cumberland Pharmaceuticals

    • Most Recent Events

    • 29 Nov 2021 According to a Cumberland Pharmaceuticals media release, U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor, an intravenously delivered formulation of ibuprofen, to now include use in pre-operative administration. The expanded use of Caldolo was supported by data from this trial.
    • 07 Dec 2011 Additional trial location (South Africa) identified as reported by ClinicalTrials.gov.
    • 30 Aug 2010 Primary endpoint 'Pain on movement' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top